Cargando…

Selumetinib-based therapy in uveal melanoma patient-derived xenografts

The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK signaling in UM have raised hopes of more effective, targeted therapies, based on MEK inhibition, for example. We evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Decaudin, Didier, El Botty, Rania, Diallo, Béré, Massonnet, Gerald, Fleury, Justine, Naguez, Adnan, Raymondie, Chloé, Davies, Emma, Smith, Aaron, Wilson, Joanne, Howes, Colin, Smith, Paul D., Cassoux, Nathalie, Piperno-Neumann, Sophie, Roman-Roman, Sergio, Némati, Fariba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955168/ https://www.ncbi.nlm.nih.gov/pubmed/29774094 http://dx.doi.org/10.18632/oncotarget.24670

Ejemplares similares

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
por: Carita, Guillaume, et al.
Publicado: (2016)

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
por: Nemati, Fariba, et al.
Publicado: (2023)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Upcoming translational challenges for uveal melanoma
por: Nabil, Amirouchene-Angelozzi, et al.
Publicado: (2015)

Upcoming translational challenges for uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2015)

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023)

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
por: Némati, Fariba, et al.
Publicado: (2014)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
por: Gentien, David, et al.
Publicado: (2023)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma
por: Mariani, Pascale, et al.
Publicado: (2023)

Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency
por: Chabot, Thomas, et al.
Publicado: (2022)

Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases
por: Barnhill, Raymond, et al.
Publicado: (2018)

Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI
por: Mariani, Pascale, et al.
Publicado: (2019)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma
por: Cassoux, Nathalie, et al.
Publicado: (2014)

Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds
por: Stimmer, Lev, et al.
Publicado: (2014)

So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020
por: Rodrigues, Manuel, et al.
Publicado: (2019)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Angiotropism and extravascular migratory metastasis in cutaneous and uveal melanoma progression in a zebrafish model
por: Fornabaio, Giulia, et al.
Publicado: (2018)

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
por: Rodrigues, Manuel, et al.
Publicado: (2018)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022)

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes
por: van Essen, T. Huibertus, et al.
Publicado: (2016)

Prognostic Implications of MRI Melanin Quantification and Cytogenetic Abnormalities in Liver Metastases of Uveal Melanoma
por: Ramtohul, Toulsie, et al.
Publicado: (2021)

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
por: Carvajal, Richard D., et al.
Publicado: (2015)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Huang, Hui-Ju, et al.
Publicado: (2021)

Effect of food on capsule and granule formulations of selumetinib
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2022)

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
por: Blegen, Kristina, et al.
Publicado: (2022)

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
por: Patel, YT, et al.
Publicado: (2017)

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
por: Dewaele, Shanna, et al.
Publicado: (2021)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bbdtkm6g8hpoj006vof56d8qd9